Immunitybio Net Income vs. Revenue
| IBRX Stock | USD 5.10 0.02 0.39% |
Net Loss | First Reported 2015-06-30 | Previous Quarter -134.6 M | Current Value -85.7 M | Quarterly Volatility 49.3 M |
For Immunitybio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Immunitybio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Immunitybio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Immunitybio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Immunitybio over time as well as its relative position and ranking within its peers.
Immunitybio |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunitybio. If investors know Immunitybio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunitybio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.011 | Quarterly Revenue Growth 73.463 | Return On Assets (0.56) |
The market value of Immunitybio is measured differently than its book value, which is the value of Immunitybio that is recorded on the company's balance sheet. Investors also form their own opinion of Immunitybio's value that differs from its market value or its book value, called intrinsic value, which is Immunitybio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunitybio's market value can be influenced by many factors that don't directly affect Immunitybio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunitybio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunitybio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunitybio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Immunitybio Revenue vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Immunitybio's current stock value. Our valuation model uses many indicators to compare Immunitybio value to that of its competitors to determine the firm's financial worth. Immunitybio is rated below average in net income category among its peers. It is rated below average in revenue category among its peers . Immunitybio reported Net Loss of (583.2 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immunitybio's earnings, one of the primary drivers of an investment's value.Immunitybio Revenue vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Immunitybio |
| = | (583.2 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Immunitybio |
| = | 622 K |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Immunitybio Revenue vs Competition
Immunitybio is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 749.77 Million. Immunitybio adds roughly 622,000 in revenue claiming only tiny portion of equities under Health Care industry.
Immunitybio Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Immunitybio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Immunitybio will eventually generate negative long term returns. The profitability progress is the general direction of Immunitybio's change in net profit over the period of time. It can combine multiple indicators of Immunitybio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 10 K | 10.5 K | |
| Operating Income | -362.2 M | -344.1 M | |
| Income Before Tax | -583.9 M | -554.7 M | |
| Total Other Income Expense Net | -221.6 M | -210.6 M | |
| Net Loss | -583.2 M | -554 M | |
| Income Tax Expense | -40 K | -42 K | |
| Interest Income | 2 M | 1.9 M | |
| Net Loss | -374.9 M | -356.2 M | |
| Net Interest Income | -123.6 M | -117.5 M | |
| Net Loss | -458.8 M | -481.7 M | |
| Non Operating Income Net Other | -2.2 M | -2.3 M | |
| Change To Netincome | 33.4 M | 25.1 M | |
| Net Loss | (1.15) | (1.20) | |
| Income Quality | 0.63 | 0.49 | |
| Net Income Per E B T | 1.00 | 1.10 |
Immunitybio Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Immunitybio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Immunitybio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Immunitybio's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Immunitybio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Volatility Analysis Now
Volatility AnalysisGet historical volatility and risk analysis based on latest market data |
| All Next | Launch Module |
Use Investing Themes to Complement your Immunitybio position
In addition to having Immunitybio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Value Funds Thematic Idea Now
Large Value Funds
Funds or Etfs that invest in the undervalued stocks of large-sized companies. The Large Value Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Value Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.